Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | endotoxin |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
References
edit- ^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.770-7&rft.date=1999-04&rft_id=info:doi/10.1086/515184&rft_id=info:pmid/10825037&rft.aulast=Derkx&rft.aufirst=B&rft.au=Wittes, J&rft.au=McCloskey, R&rft_id=https://doi.org/10.1086%2F515184&rfr_id=info:sid/en.wikipedia.org:Nebacumab" class="Z3988">
- ^ WHO: Consolidated List of Products
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |